Nick McFarland

Nick McFarland, MD, PhD

Associate Professor

Department: MD-NEUROLOGY-MOVEMENT DISORDER
Business Phone: (352) 273-5550

About Nick McFarland

Nikolaus McFarland, MD, PhD, joined the UF Department of Neurology and the UF Health Center for Movement Disorders & Neurorestoration in 2010. He graduated from the University of Chicago in 1992 with honors in biology and election into the Sigma Xi research society. He completed medical and graduate training in the MD-PhD program at the University of Rochester School of Medicine & Dentistry, where he received a merit award for outstanding graduate research in basal ganglia-thalamic anatomy. Afterwards, he went to the University of Virginia for internship and residency training in neurology, and then pursued fellowship training in movement disorders at the Massachusetts General Hospital. While a fellow and junior faculty member at MGH/Harvard he pursued research in Parkinson disease and related disorders. As a Udall Fellow, he became the first recipient of the Robert Koch Parkinson Disease research fellowship. He has since received research grant support from the American Parkinson Disease Association, Michael J. Fox Foundation, and the National Institutes of Health.

Accomplishments

Fellow Member of the American Academy of Neurology
2017 · American Academy of Neurology
UF Excellence Award for Assistant Professors
2014 · University of Florida College of Medicine
Wright/Falls/Simmons Professorship in PSP/Atypical Parkinson’s disease
2013 · University of Florida College of Medicine
Didactic Teacher of the Year Award
2013 · University of Florida, Neurology Residents
Robert N. Koch Jr. Fellowship in Parkinson’s Disease Research
2008 · Massachusetts General Hospital
Neurology Resident Teaching Award
2006 · University of Virginia Health System, Neurology Department
Udall Fellowship in Movement Disorders
2006 · Massachusetts General Hospital

Board Certifications

  • Neurology
    ABPN

Clinical Profile

Specialties
  • Neurology
Areas of Interest
  • Basal ganglia dysfunction
  • Deep brain stimulation
  • Dystonia
  • Essential tremor
  • Huntington disease
  • Movement – uncontrollable
  • Movement – uncontrolled or slow
  • Movement – uncoordinated
  • Movement – unpredictable or jerky
  • Multiple system atrophy – parkinsonian type
  • Parkinson disease
  • Progressive supranuclear palsy
  • Tremor

Research Profile

Dr. McFarland is an active member of the Center for Translational Research in Neurodegenerative Disease (CTRND) which aims to bring the bench closer to the bedside. His research focuses on understanding the pathological mechanisms of Parkinson disease and related disorders, and in particular the role of alpha-synuclein in cell toxicity and neurodegeneration. His current studies utilize both cellular and preclinical models to study genes and molecules that may affect brain pathology. A primary goal of his research is to identify and to develop potential novel therapeutics for Parkinson disease and related disorders. His research extends also to the clinic where he is actively involved in multiple clinical trials for atypical Parkinson disorders and Huntington disease.

Open Researcher and Contributor ID (ORCID)

0000-0002-8699-8857

Publications

2017
Depressive Symptoms Are Frequent in Atypical Parkinsonian Disorders
Movement Disorders Clinical Practice. 4(2):191-197 [DOI] 10.1002/mdc3.12382.
2017
Progression Marker of Parkinson’s Disease: a 4-Year Multi-Site Imaging Study
Brain. 140(8):2183-2192 [DOI] 10.1093/brain/awx146.
2017
The Er Retention Protein Rer1 Promotes Alpha-Synuclein Degradation Via the Proteasome
PLoS One. 12(9) [DOI] 10.1371/journal.pone.0184262. [PMID] 28877262.
2017
Functional Activity of the Sensorimotor Cortex and Cerebellum Relates to Cervical Dystonia Symptoms
Human brain mapping. 38(9):4563-4573 [DOI] 10.1002/hbm.23684. [PMID] 28594097.
2015
Abnormal Tactile Pressure Perception in Parkinson’s Disease
Journal of Clinical and Experimental Neuropsychology. 37(8):808-815 [DOI] 10.1080/13803395.2015.1060951. [PMID] 26313511.
2015
Distinct Functional and Macrostructural Brain Changes in Parkinson’s Disease and Multiple System Atrophy
Human brain mapping. 36(3):1165-1179 [DOI] 10.1002/hbm.22694. [PMID] 25413603.
2015
Global Attentional Neglect of Segmented Lines in Parkinson’s Disease
Neurocase. 21(4):501-508 [DOI] 10.1080/13554794.2014.942671. [PMID] 25073971.
2015
Unexpected dual task benefits on cycling in Parkinson disease and healthy adults: a neuro-behavioral model.
PloS one. 10(5) [DOI] 10.1371/journal.pone.0125470. [PMID] 25970607.
2015
Weight Loss and Impact On Quality of Life in Parkinson’s Disease
PLoS One. 10(5) [DOI] 10.1371/journal.pone.0124541. [PMID] 25938478.
2014
An Eight-Year Clinic Experience With Clozapine Use in a Parkinson’s Disease Clinic Setting
PLoS One. 9(3) [DOI] 10.1371/journal.pone.0091545. [PMID] 24646688.
2014
Chronic Treatment With Novel Small Molecule Hsp90 Inhibitors Rescues Striatal Dopamine Levels But Not Alpha-Synuclein-Induced Neuronal Cell Loss
PLoS One. 9(1) [DOI] 10.1371/journal.pone.0086048. [PMID] 24465863.
2014
Defining the clinically meaningful difference in gait speed in persons with Parkinson disease.
Journal of neurologic physical therapy : JNPT. 38(4):233-8 [DOI] 10.1097/NPT.0000000000000055. [PMID] 25198866.
2014
MRI reveals brain abnormalities in drug-naive Parkinson’s disease.
Exercise and sport sciences reviews. 42(1):12-22 [DOI] 10.1249/JES.0000000000000003. [PMID] 24188978.
2014
The ‘Brittle Responseandquot; To Parkinson’s Disease Medications: Characterization and Response To Deep Brain Stimulation
PLoS One. 9(4) [DOI] 10.1371/journal.pone.0094856. [PMID] 24733172.
2014
The Exam Starts in the Hallway: Movement Disorders in Geriatric Psychiatry
The American Journal Of Geriatric Psychiatry. 22(3, S):S32-S33
2013
Advancing Research Towards Novel Therapeutic Approaches
Nature reviews. Neurology. 9(2):70-71 [DOI] 10.1038/nrneurol.2012.265. [PMID] 23296342.
2013
Anti-Tau Antibodies: Hitting the Target
Neuron. 80(2):254-256 [DOI] 10.1016/j.neuron.2013.10.009. [PMID] 24139027.
2013
Driving Performance and Behaviors: a Comparison of Gender Differences in Parkinson’s Disease
Traffic Injury Prevention. 14(4):340-345 [DOI] 10.1080/15389588.2012.717730. [PMID] 23531256.
2013
Efficient Determination of Purine Metabolites in Brain Tissue and Serum By High-Performance Liquid Chromatography With Electrochemical and Uv Detection
Biomedical Chromatography. 27(1):122-129 [DOI] 10.1002/bmc.2760. [PMID] 22674671.
2013
Postmortem Brain Levels of Urate and Precursors in Parkinson’s Disease and Related Disorders
Neurodegenerative Diseases. 12(4):189-198 [DOI] 10.1159/000346370. [PMID] 23467193.
2013
Postural/Gait and cognitive function as predictors of driving performance in Parkinson’s disease.
Journal of Parkinson's disease. 3(2):153-60 [DOI] 10.3233/JPD-120152. [PMID] 23938345.
2013
Variability in clinical phenotypes of heterozygous and homozygous cases of Parkin-related Parkinson’s disease.
The International journal of neuroscience. 123(12):847-9 [DOI] 10.3109/00207454.2013.810626. [PMID] 23767969.
2012
Are Selective Serotonin Reuptake Inhibitors Associated With Greater Apathy in Parkinson’s Disease?
Journal of Neuropsychiatry and Clinical Neurosciences. 24:326-330
2012
Deep Brain Stimulation Response in Pathologically Confirmed Cases of Multiple System Atrophy
Parkinsonism & Related Disorders. 18(1):86-88 [DOI] 10.1016/j.parkreldis.2011.09.008. [PMID] 21983018.
2012
Neurogenic Potential of Progenitor Cells Isolated From Postmortem Human Parkinsonian Brains
Brain Research. 1464:61-72 [DOI] 10.1016/j.brainres.2012.04.039. [PMID] 22652067.
2012
Quantitative normative gait data in a large cohort of ambulatory persons with Parkinson’s disease.
PloS one. 7(8) [DOI] 10.1371/journal.pone.0042337. [PMID] 22879945.
2011
Interferon-Gamma Induces Progressive Nigrostriatal Degeneration and Basal Ganglia Calcification
Nature Neuroscience. 14(6):694-696 [DOI] 10.1038/nn.2829. [PMID] 21572432.

Grants

Jun 2020 ACTIVE
1Florida Alzheimers Disease Research Center
Role:
Funding: NATL INST OF HLTH NIA
Jan 2020 ACTIVE
Huntington's Disease Center of Excellence 2020
Role: Principal Investigator
Funding: HUNTINGTONS DISEASE SOCIETY OF AMERICA
Dec 2019 ACTIVE
LRRK2-Synuclein Interactions with Gut Inflammation in PD Pathogenesis
Role:
Funding: PARKINSONS FOU
Jan 2019 – Dec 2019
Huntingtons Disease Society of America Centers of Excellence Program
Role: Principal Investigator
Funding: HUNTINGTONS DISEASE SOCIETY OF AMERICA
Jul 2018 – Jun 2019
Huntingtons Disease Society of America Centers of Excellence Program
Role: Principal Investigator
Funding: HUNTINGTONS DISEASE SOCIETY OF AMERICA
Jan 2018 ACTIVE
Proteinopathy in Atypical Parkinson disorders
Role: Principal Investigator
Funding: UF FOU
Sep 2017 ACTIVE
Neuroimaging Biomarkers in Parkinsonism: Differentiating Subtypes and Tracking Disease Progression
Role:
Funding: NATL INST OF HLTH NINDS
Jul 2017 – Jun 2018
Huntingtons Disease Society of America Centers of Excellence Program
Role: Principal Investigator
Funding: HUNTINGTONS DISEASE SOCIETY OF AMERICA
Jun 2017 – Jun 2018
Parkinson Foundation Center of Excellence
Role:
Funding: NATL PARKINSON FOU
May 2017 – Jun 2020
Role of HLA/MHCII in Parkinson's Disease Pathogenesis
Role: Principal Investigator
Funding: EMORY UNIV via NATL INST OF HLTH NINDS
Jan 2017 ACTIVE
Targeting Synucleinopathy in Multiple System Atrophy Parkinsonism
Role: Principal Investigator
Funding: UF FOU
Aug 2016 ACTIVE
Scaling and Sequencing Motor Output in Humans: fMRI Study
Role:
Funding: NATL INST OF HLTH NINDS
Jul 2016 – Jun 2017
Huntington?s Disease Society of America Centers of Excel
Role: Principal Investigator
Funding: HUNTINGTONS DISEASE SOCIETY OF AMERICA
Jul 2016 – Jun 2017
National Parkinson Foundation (NPF) Center of Excellence
Role:
Funding: NATL PARKINSON FOU
Feb 2016 – Feb 2022
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously AdministeredBMS-986168 in Patients with Progressive Supranuclear Palsy Who Participated inStudy CN002003
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Dec 2015 – Apr 2017
TARGETING RER1 IN MODELS OF PARKINSON'S DISEASE
Role: Principal Investigator
Funding: FOX FOU, MICHAEL J
Sep 2015 – Sep 2018
a randomized double blind placebo controlled multiple
Role: Principal Investigator
Funding: COVANCE INC via BRISTOL MYERS SQUIBB CO
Jul 2015 ACTIVE
Role of Cortex and Cerbellum in Visually-Guided Motor Behavior
Role: Project Manager
Funding: NATL INST OF HLTH NINDS
May 2015 – Jun 2019
RAB PROTEINS AND ALPHA
Role: Principal Investigator
Funding: FL CLINICAL PRACTICE ASSO
Sep 2013 – Aug 2019
White Matter Connectivity and PD Cognitive Phenotypes
Role:
Funding: NATL INST OF HLTH NINDS
Aug 2010 – Jul 2016
Rab proteins and alpha-Synuclein toxicity in Neurodegene
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS

Teaching Profile

Courses Taught
2020
GMS6757 Introduction to Alzheimer’s Disease and Related Dementias: Clinical and Mechanistic Principles
2018-2019
GMS6705 Functional Human Neuroanatomy
2018
GMS7980 Research for Doctoral Dissertation
2013,2016-2017
GMS6750 Molecular Pathobiology of Neural Disease
2013,2015-2016
GMS6029 Brain Journal Club

Contact Details

Phones:
Business:
(352) 273-5550